Are these ASX blue chips now too cheap to ignore?

Let's see why these shares could be seriously undervalued at current levels.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even the highest-quality companies are not immune to market selloffs.

In fact, periods of uncertainty often see investors pull back from even the most established names. While that can be uncomfortable in the short term, it can also create opportunities to buy leading businesses at more attractive prices.

Here are three ASX blue chips that have fallen heavily and could be worth a closer look.

Couple looking at their phone surprised, symbolising a bargain buy.

Image source: Getty Images

Cochlear Ltd (ASX: COH)

The first ASX blue chip that could be too cheap to ignore is Cochlear.

The hearing solutions company recently disappointed the market with a softer-than-expected result, driven in part by a slower rollout of its new Nexa system and margin pressure from product mix.

While this has weighed on sentiment, it does not change Cochlear's long-term position as a global leader in implantable hearing devices.

Demand for hearing solutions continues to grow due to ageing populations and increased awareness. Cochlear also benefits from a large installed base, which generates recurring revenue through upgrades and servicing.

If the company can execute on its product rollout and return to stronger growth, the current weakness could prove temporary.

CSL Ltd (ASX: CSL)

Another ASX blue chip that may be worth considering is CSL.

The biotech giant's shares have fallen sharply following a soft result and the unexpected CEO transition, which has created uncertainty around its near-term outlook.

The key issue has been weaker-than-expected performance in its CSL Behring division, particularly in immunoglobulin, alongside slower margin recovery than the market had anticipated.

However, CSL still operates in global healthcare markets with strong demand and high barriers to entry. Its therapies address serious medical conditions, and long-term growth drivers remain intact.

While challenges remain, the company's track record and market position suggest it has the capability to work through this period and return to more consistent growth.

James Hardie Industries plc (ASX: JHX)

A third ASX blue chip that could be trading at an attractive level is James Hardie Industries.

The building materials company has been under pressure due to concerns about housing market weakness, particularly in the United States.

Slower construction activity can weigh on demand for its fibre cement products, which has led to more cautious sentiment from investors.

However, James Hardie remains a leader in its category, with strong brand recognition and a history of gaining market share over time.

When housing activity eventually recovers, the company could be well placed to benefit. In the meantime, it continues to focus on innovation and expanding its product offering.

For investors willing to look beyond the near-term uncertainty, this could make it an interesting option at current levels.

Motley Fool contributor James Mickleboro has positions in CSL and Cochlear. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Cochlear. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Young woman thinking with laptop open.
Blue Chip Shares

Why is everyone selling Wesfarmers shares?

It looks like the retail conglomerate fell out of favour with investors this year.

Read more »

Four business people wearing formal business suits and ties walk abreast on a wide paved surface with their long shadows falling on the ground ahead of them.
Blue Chip Shares

How did these ASX blue-chip shares perform in March?

Did these blue-chips beat the market in March?

Read more »

A woman gives two fist pumps with a big smile as she learns of her windfall, sitting at her desk.
Blue Chip Shares

3 reasons to buy Wesfarmers shares today

The retail conglomerate is a no-brainer buy in my book.

Read more »

ASX shares buy Street signs stating 'Winners' and 'Losers' in front of urban backdrop
Blue Chip Shares

How are these 5 ASX share giants really tracking in 2026?

Some are struggling, while others are thriving, proving that opportunity is never far away.

Read more »

Happy work colleagues give each other a fist pump.
Blue Chip Shares

My best blue-chip ASX 200 buys for April

Looking for quality in uncertain markets? These three ASX 200 shares stand out to me.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »

A happy woman stands outside a building looking at her phone and smiling widely.
Blue Chip Shares

I think smart investors should buy these ASX 200 blue-chip shares with $10,000

Looking for ideas? Here are three ASX 200 blue chips that could help build long-term wealth.

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Blue Chip Shares

Would I buy BHP, CBA, and CSL shares today?

These three ASX 200 leaders have taken different paths lately. Here’s how I’d think about them right now.

Read more »